227:(MIT) in Cambridge, Massachusetts. While at MIT, Sadelain began his research on genetic engineering. In 1994, Sadelain joined Memorial Sloan Kettering as an assistant member in the Sloan Kettering Institute, where he established programs on human hematopoietic stem cell and T cell engineering. In 2008, he founded the Center for Cell Engineering at Memorial Sloan Kettering. He is a past president of the American Society of Cell and Gene Therapy (2014–2015) and previously served on its board of directors from 2004 to 2007. He served as a member of the Recombinant DNA Advisory Committee (RAC) of the
244:) to recognize the cancer and a modular signaling domain to activate the T cell and promote T cell multiplication and persistence. CAR T cells are made by extracting a cancer patient's T cells, inserting a CAR into the cell using a vector such as a gamma-retroviral or lentiviral vector, and then re-infusing the genetically instructed T cells. Sadelain's current research makes use of genome editing, which he showed makes better CAR T cells when the CAR is expressed from the
31:
195:, New York, New York, where he holds the Steve and Barbara Friedman Chair. He is the founding director of the Center for Cell Engineering and the head of the Gene Transfer and Gene Expression Laboratory. He is a member of the department of medicine at Memorial Hospital and of the immunology program at the Sloan Kettering Institute. He is best known for his major contributions to T cell engineering and
252:
cell manufacturing by Dr. Isabelle Rivière at MSK, Sadelain's team was the first to report on molecular complete responses induced by CD19 CAR T cells in adults with relapsed, refractory acute lymphoblastic leukemia. The MSK team received FDA breakthrough designation for this treatment in 2014. The US FDA approved the first CAR therapies, targeting CD19 with second generations CARs, in 2017.
259:(iPSCs) is now being developed in a collaboration with Fate Therapeutics. His research with Dr. Prasad S. Adusumilli led to a collaboration with Atara Biotherapeutics, Inc. for a product candidate to treat malignant mesothelioma using mesothelin-targeted CAR T cells named icasM28z. In 2013, Sadelain co-founded Juno Therapeutics Inc.
279:
Sadelain holds numerous patents in immunotherapy. Sadelain is a named inventor on U.S. Patent No. 7446190B2 covering nucleic acids encoding chimeric T cell receptors. Sadelain is also named on patent U.S. Patent No. 10,370,452 covering compositions and uses of effector T cells expressing a chimeric
239:
Sadelain and his team study gene transfer in hematopoietic stem cells and T cells, the regulation of transgene expression, the biology of chimeric antigen receptors, and therapeutic strategies to enhance immunity against cancer. Sadelain is a recognized leader in the conceptualization and design of
364:
2011- Renier J. Brentjens, Isabelle Rivière, Jae H. Park, Marco L. Davila, Xiuyan Wang, Jolanta
Stefanski, Clare Taylor, Raymond Yeh, Shirley Bartido, Oriana Borquez-Ojeda, Malgorzata Olszewska, Yvette Bernal, Hollie Pegram, Mark Przybylowski, Daniel Hollyman, Yelena Usachenko, Domenick Pirraglia,
251:
Sadelain's laboratory designed second generation CARs, which are endowed with both activating and costimulatory properties, which is integral to the success of CAR therapies. In 2003, Sadelain's lab identified CD19 as a target for CAR therapy in mice. Following the establishment of clinical CAR T
270:
and sickle cell disease. The MSK team was the first to treat patients with β-thalassemia in the US. The history of the field and
Sadelain's contributions are narrated in the 2021 George Stamatoyannopoulos Memorial Lecture at the annual meeting of the American Society of Gene and Cell Therapy.
240:
synthetic receptors for antigen, which he named chimeric antigen receptors (CARs). T cells can be engineered to express a CAR to acquire the ability to recognize and destroy cancer cells. Sadelain has referred to CAR T cells as a “living drug.” A CAR typically comprises an antibody fragment (
399:
2014- Davila, Marco L.; Riviere, Isabelle; Wang, Xiuyan; Bartido, Shirley; Park, Jae; Curran, Kevin; Chung, Stephen S.; Stefanski, Jolanta; Borquez-Ojeda, Oriana; Olszewska, Malgorzata; Qu, Jinrong (2014-02-19). "Efficacy and
Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute
280:
antigen receptor (CAR), where such T cells are derived from a pluripotent stem cell including an induced pluripotent stem cell (iPSC). The patent is licensed for off-the-shelf, T-cell receptor (TCR)-less CD19 chimeric antigen receptor (CAR) T-cell product candidate known as FT819.
1497:
353:
2009- Hollyman, Daniel; Stefanski, Jolanta; Przybylowski, Mark; Bartido, Shirley; Borquez-Ojeda, Oriana; Taylor, Clare; Yeh, Raymond; Capacio, Vanessa; Olszewska, Malgorzata; Hosey, James; Sadelain, Michel, Riviere, Isabelle (2009).
374:
2013- Brentjens, Renier J.; Davila, Marco L.; Riviere, Isabelle; Park, Jae; Wang, Xiuyan; Cowell, Lindsay G.; Bartido, Shirley; Stefanski, Jolanta; Taylor, Clare; Olszewska, Malgorzata; Borquez-Ojeda, Oriana (2013-03-20).
1095:
Brentjens, Renier J.; Davila, Marco L.; Riviere, Isabelle; Park, Jae; Wang, Xiuyan; Cowell, Lindsay G.; Bartido, Shirley; Stefanski, Jolanta; Taylor, Clare; Olszewska, Malgorzata; Borquez-Ojeda, Oriana (2013-03-20).
336:
2003- Brentjens, Renier J.; Latouche, Jean-Baptiste; Santos, Elmer; Marti, Francesc; Gong, Michael C.; Lyddane, Clay; King, Philip D.; Larson, Steven; Weiss, Mark; Rivière, Isabelle; Sadelain, Michel (2003–03).
424:
2018- Park, Jae H.; Rivière, Isabelle; Gonen, Mithat; Wang, Xiuyan; Sénéchal, Brigitte; Curran, Kevin J.; Sauter, Craig; Wang, Yongzeng; Santomasso, Bianca; Mead, Elena; Roshal, Mikhail (2018-02-01).
723:
410:
2017- Eyquem, Justin; Mansilla-Soto, Jorge; Giavridis, Theodoros; van der Stegen, Sjoukje J. C.; Hamieh, Mohamad; Cunanan, Kristen M.; Odak, Ashlesha; Gönen, Mithat; Sadelain, Michel (2017–03).
903:
Eyquem, Justin; Mansilla-Soto, Jorge; Giavridis, Theodoros; van der Stegen, Sjoukje J. C.; Hamieh, Mohamad; Cunanan, Kristen M.; Odak, Ashlesha; Gönen, Mithat; Sadelain, Michel (March 2017).
199:, an immunotherapy based on the genetic engineering of a patient's own T cells to treat cancer. Dr. Sadelain is an elected member of the National Academy of Medicine of France and the
1235:
1473:
1071:
476:
465:
220:
1725:
1448:
367:"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias"
789:
1701:
968:
482:
365:
James Hosey, Elmer Santos, Elizabeth Halton, Peter Maslak, David
Scheinberg, Joseph Jurcic, Mark Heaney, Glenn Heller, Mark Frattini, Michel Sadelain
470:
1757:
1865:
291:"Antigen-dependent CD28 Signaling Selectively Enhances Survival and Proliferation in Genetically Modified Activated Human Primary T Lymphocytes"
494:
366:
200:
192:
153:
1895:
1652:
761:
584:
224:
347:
330:
299:
871:
553:
547:
391:"Generation of functional tumor-targeted T lymphocytes from human chimeric antigen receptor- engineered induced pluripotent stem cells."
124:
118:
1153:
724:"La Fondation ARC félicite le chercheur français Michel Sadelain, nouveau lauréat du prestigieux Breakthrough Prize en Life Science"
1310:
May, Chad; Rivella, Stefano; Callegari, John; Heller, Glenn; Gaensler, Karen M. L.; Luzzatto, Lucio; Sadelain, Michel (July 2000).
196:
320:
2002- Maher, John; Brentjens, Renier J.; Gunset, Gertrude; Rivière, Isabelle; Sadelain, Michel Nat
Biotechnol 20, 70–75 (2002).
1900:
1098:"CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia"
377:"CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia"
290:
1474:"Fate Therapeutics Announces Issuance of Foundational U.S. Patent Covering iPSC-derived CAR T Cells | Fate Therapeutics, Inc"
559:
488:
439:
2018- Dunbar, Cynthia E.; High, Katherine A.; Joung, J. Keith; Kohn, Donald B.; Ozawa, Keiya; Sadelain, Michel (2018-01-12).
289:
1998- Krause, Anja; Guo, Hong-Fen; Latouche, Jean-Baptiste; Tan, Cuiwen; Cheung, Nai-Kong V.; Sadelain, Michel (1998-08-17).
241:
130:
1546:
339:"Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15"
356:"Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy"
311:
2000- Chad May, Stefano
Rivella, John Callegari, Glenn Heller, Karen M. L. Gaensler, Lucio Luzzatto & Michel Sadelain
228:
1283:
1236:"Preliminary Results Show Activity for Mesothelin‑Directed CAR T-Cell Therapy in Malignant Mesothelioma - The ASCO Post"
541:
1816:
1858:
1373:
1872:
1259:
341:
324:
293:
1586:
671:
636:
428:. New England Journal of Medicine. 378 (5): 449–459. doi:10.1056/NEJMoa1709919. ISSN 0028-4793. PMC 6637939.
1521:
1610:
510:
256:
1016:
Maher, John; Brentjens, Renier J.; Gunset, Gertrude; Rivière, Isabelle; Sadelain, Michel (January 2002).
1851:
1749:
1018:"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor"
216:
1879:
1312:"Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin"
1677:
1323:
916:
322:"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor"
313:
Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin
1780:"Breakthrough Prize Announces 2024 Laureates in Life Sciences, Fundamental Physics, and Mathematics"
369:
358:
212:
184:
1425:"Analytics for US Patent No. 8399645, Chimeric receptors with 4-1BB stimulatory signaling domain"
1355:
1217:
1053:
263:
262:
Sadelain also designed lentiviral vectors encoding the β-globin gene for the treatment of severe
1374:"2021 ASGCT George Stamatoyannopoulos Memorial Lecture | Memorial Sloan Kettering Cancer Center"
30:
1568:
1347:
1339:
1209:
1201:
1135:
1117:
1045:
1037:
950:
932:
879:
852:
834:
644:
444:
429:
380:
303:
1558:
1331:
1191:
1125:
1109:
1029:
940:
924:
842:
826:
519:
267:
376:
1844:
611:
171:
1327:
992:
920:
355:
1130:
1097:
945:
904:
847:
814:
790:"Prominent Immunotherapy Researcher Sees Success Beyond the Challenges - The ASCO Post"
1400:
440:
425:
1889:
1678:"Gabbay award given to scientists whose research brought about new cancer treatments"
1401:"Michel Sadelain Inventions, Patents and Patent Applications - Justia Patents Search"
296:
1563:
1221:
1057:
1359:
188:
1072:"The Possibilities and Risks of Genetically Altering Immune Cells to Fight Cancer"
585:"Two Memorial Sloan Kettering Experts Awarded for Pioneering Work - The ASCO Post"
1653:"World-Renowned Immunologist Michel Sadelain Wins Pasteur-Weizmann/Servier Prize"
1113:
401:
316:
969:"'Living Drug' That Fights Cancer By Harnessing Immune System Clears Key Hurdle"
389:
2013- Themeli M, Kloss C, Ciriello G, Fedorov VD, Perna F, Gonen M, Sadelain M.
1196:
1179:
327:
905:"Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection"
830:
443:. Science. 359 (6372): eaan4672. doi:10.1126/science.aan4672. ISSN 0036-8075.
415:
412:"Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection"
411:
1628:
1572:
1343:
1205:
1154:"Cell Therapy Shows Remarkable Ability to Eradicate Cancer in Clinical Study"
1121:
1041:
936:
883:
838:
648:
321:
1424:
1017:
390:
1498:"Patent Database Search Results: "michel sadelain" in US Patent Collection"
1351:
1311:
1213:
1139:
1049:
954:
856:
448:
433:
419:
394:
384:
312:
306:
699:
404:
211:
Sadelain was born in 1960 in Paris, France, where he earned his MD at the
426:"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia"
219:
in
Edmonton, Canada, in 1989, he trained as a postdoctoral fellow at the
1779:
1449:"Fate Therapeutics, MSK to Develop Off-the-Shelf T-Cell Immunotherapies"
928:
338:
255:
Sadelain's research on “off-the-shelf” CAR T cells derived from induced
1726:"The Golden Age of Gene Therapy: Past, Present and Future Perspectives"
1033:
1335:
813:
Sadelain, Michel; Brentjens, Renier; Rivière, Isabelle (April 2009).
344:
1804:
815:"The promise and potential pitfalls of chimeric antigen receptors"
528:
215:, France, in 1984. After obtaining his PhD in immunology at the
102:
676:
Académie nationale de médecine | Une institution dans son temps
1866:
1284:"Letter Agreement, Memorial Sloan Kettering Cancer Center"
1817:"2024 Warren Alpert Foundation Prize awardees Announced"
1545:
Research, American Association for Cancer (2013-04-18).
872:"Cell Therapy Shows Promise for Acute Type of Leukemia"
515:
2013 Sultan Bin Khalifa International Thalassemia Award
666:
664:
1859:
2021 ASGCT George Stamatoyannopoulos Memorial Lecture
637:"How Scientists Built a 'Living Drug' to Beat Cancer"
35:
Michel Sadelain, Genetic Engineer and Cell Therapist
166:
146:
92:
72:
52:
40:
21:
704:American Academy of Arts and Sciences (amacad.org)
1611:"Michel Sadelain recognized for Thalassemia work"
1852:2021 ASGCT Outstanding Achievement Award Lecture
1750:"Citation Laureates 2023_Physiology or Medicine"
1453:GEN - Genetic Engineering and Biotechnology News
756:
754:
752:
750:
748:
746:
744:
579:
577:
575:
379:doi10.1126/scitranslmed.3005930ISSN 1946-6234
1305:
1303:
8:
694:
692:
525:2018 Pasteur-Weizmann/Servier Prize Laureate
370:doi10.1182/blood-2011-04-348540ISSN0006-4971
1821:Warren Alpert Foundation (warrenalpert.org)
1702:"Michel Sadelain, 2019 International Prize"
728:Fondation ARC de la recherche sur le cancer
477:American Society for Clinical Investigation
466:American Society for Clinical Investigation
221:Whitehead Institute for Biomedical Research
65:Massachusetts Institute of Technology (MIT)
784:
782:
780:
29:
18:
1562:
1395:
1393:
1195:
1129:
944:
846:
483:American Society of Gene and Cell Therapy
1805:Canada Gairdner International Award 2024
537:2021 ASGCT Outstanding Achievement Award
471:American Association for Cancer Research
111:2021 ASGCT Outstanding Achievement Award
1760:from the original on September 19, 2023
606:
604:
571:
495:American Academy of Arts & Sciences
361:ISSN 1524-9557 PMC2683970 PMID 19238016
201:American Academy of Arts & Sciences
197:chimeric antigen receptor (CAR) therapy
82:chimeric antigen receptor (CAR) therapy
1657:Memorial Sloan Kettering Cancer Center
499:National Academy of Medicine of France
193:Memorial Sloan Kettering Cancer Center
154:Memorial Sloan Kettering Cancer Center
1522:"CRI Clinical Accelerator Leadership"
993:"Inside Cancer's Newest Miracle Cure"
225:Massachusetts Institute of Technology
7:
554:Canada Gairdner International Award
548:Breakthrough Prize in Life Sciences
125:Canada Gairdner International Award
119:Breakthrough Prize in Life Sciences
14:
1547:"Driving Ahead with CAR T Cells"
672:"Fiche membre – Michel SADELAIN"
1706:Inserm - From science to health
1564:10.1158/2159-8290.CD-NB2013-059
1178:Sadelain, Michel (2017-12-14).
531:2019 INSERM International Prize
402:doi10.1126/scitranslmed.3008226
359:doi10.1097/CJI.0b013e318194a6e8
105:2019 INSERM International Prize
1260:"Biotech's Coming Cancer Cure"
1102:Science Translational Medicine
762:"Michel Sadelain, M.D., Ph.D."
560:Warren Alpert Foundation Prize
489:American Society of Hematology
131:Warren Alpert Foundation Prize
1:
819:Current Opinion in Immunology
522:and Physician Scientist Award
414:Nature. 543 (7643): 113–117.
1896:American medical researchers
1873:Biotech’s Coming Cancer Cure
1114:10.1126/scitranslmed.3005930
870:Grady, Denise (2013-03-20).
542:Clarivate Citation Laureates
315:, Nature 406, 82–86 (2000).
1633:The Passano Foundation, Inc
534:2020 Leopold Griffuel Award
441:"Gene therapy comes of age"
108:2020 Leopold Griffuel Award
1917:
1197:10.1016/j.cell.2017.12.002
461:CRI Accelerator Leadership
1591:Cancer Research Institute
1526:Cancer Research Institute
831:10.1016/j.coi.2009.02.009
765:Cancer Research Institute
612:"The Michel Sadelain Lab"
162:
139:
28:
1587:"William B. Coley Award"
400:Lymphoblastic Leukemia"
284:Significant publications
114:2023 AACR Elected Fellow
23:Michel Sadelain, MD, PhD
1845:The Michel Sadelain Lab
1478:ir.fatetherapeutics.com
730:(in French). 2023-10-24
416:doi:10.1038/nature21405
172:The Michel Sadelain Lab
1901:American immunologists
700:"2024 New Member List"
511:William B. Coley Award
393:Nature Biotechnology.
257:pluripotent stem cells
1264:MIT Technology Review
297:10.1084/jem.188.4.619
217:University of Alberta
62:University of Alberta
16:American immunologist
1786:. September 14, 2023
1076:Smithsonian Magazine
1022:Nature Biotechnology
207:Education and career
1880:The CAR T-Cell Race
1429:www.patentbuddy.com
1328:2000Natur.406...82M
929:10.1038/nature21405
921:2017Natur.543..113E
395:2013;31(10):928-33.
231:from 2013 to 2015.
213:University of Paris
85:Globin gene therapy
59:University of Paris
1784:BREAKTHROUGH PRIZE
1754:Citation Laureates
1405:patents.justia.com
1180:"CD19 CAR T Cells"
1034:10.1038/nbt0102-70
876:The New York Times
328:10.1038/nbt0102-70
264:hemoglobinopathies
183:(born 1960) is an
99:2018 Passano Award
79:T cell engineering
915:(7643): 113–117.
178:
177:
141:Scientific career
1908:
1882:
1875:
1868:
1861:
1854:
1847:
1831:
1830:
1828:
1827:
1813:
1807:
1802:
1796:
1795:
1793:
1791:
1776:
1770:
1769:
1767:
1765:
1746:
1740:
1739:
1737:
1736:
1722:
1716:
1715:
1713:
1712:
1698:
1692:
1691:
1689:
1688:
1674:
1668:
1667:
1665:
1664:
1649:
1643:
1642:
1640:
1639:
1625:
1619:
1618:
1607:
1601:
1600:
1598:
1597:
1583:
1577:
1576:
1566:
1557:(6): 595.2–596.
1551:Cancer Discovery
1542:
1536:
1535:
1533:
1532:
1518:
1512:
1511:
1509:
1508:
1494:
1488:
1487:
1485:
1484:
1470:
1464:
1463:
1461:
1460:
1445:
1439:
1438:
1436:
1435:
1421:
1415:
1414:
1412:
1411:
1397:
1388:
1387:
1385:
1384:
1370:
1364:
1363:
1336:10.1038/35017565
1307:
1298:
1297:
1295:
1294:
1280:
1274:
1273:
1271:
1270:
1256:
1250:
1249:
1247:
1246:
1232:
1226:
1225:
1199:
1175:
1169:
1168:
1166:
1165:
1150:
1144:
1143:
1133:
1108:(177): 177ra38.
1092:
1086:
1085:
1083:
1082:
1068:
1062:
1061:
1013:
1007:
1006:
1004:
1003:
989:
983:
982:
980:
979:
965:
959:
958:
948:
900:
894:
893:
891:
890:
867:
861:
860:
850:
810:
804:
803:
801:
800:
794:www.ascopost.com
786:
775:
774:
772:
771:
758:
739:
738:
736:
735:
720:
714:
713:
711:
710:
696:
687:
686:
684:
683:
668:
659:
658:
656:
655:
633:
627:
626:
624:
622:
608:
599:
598:
596:
595:
581:
520:Passano Laureate
266:, which include
185:genetic engineer
174:
33:
19:
1916:
1915:
1911:
1910:
1909:
1907:
1906:
1905:
1886:
1885:
1878:
1871:
1864:
1857:
1850:
1843:
1840:
1835:
1834:
1825:
1823:
1815:
1814:
1810:
1803:
1799:
1789:
1787:
1778:
1777:
1773:
1763:
1761:
1748:
1747:
1743:
1734:
1732:
1724:
1723:
1719:
1710:
1708:
1700:
1699:
1695:
1686:
1684:
1676:
1675:
1671:
1662:
1660:
1651:
1650:
1646:
1637:
1635:
1627:
1626:
1622:
1615:stemcell.ny.gov
1609:
1608:
1604:
1595:
1593:
1585:
1584:
1580:
1544:
1543:
1539:
1530:
1528:
1520:
1519:
1515:
1506:
1504:
1502:patft.uspto.gov
1496:
1495:
1491:
1482:
1480:
1472:
1471:
1467:
1458:
1456:
1447:
1446:
1442:
1433:
1431:
1423:
1422:
1418:
1409:
1407:
1399:
1398:
1391:
1382:
1380:
1372:
1371:
1367:
1322:(6791): 82–86.
1309:
1308:
1301:
1292:
1290:
1282:
1281:
1277:
1268:
1266:
1258:
1257:
1253:
1244:
1242:
1234:
1233:
1229:
1177:
1176:
1172:
1163:
1161:
1152:
1151:
1147:
1094:
1093:
1089:
1080:
1078:
1070:
1069:
1065:
1015:
1014:
1010:
1001:
999:
991:
990:
986:
977:
975:
967:
966:
962:
902:
901:
897:
888:
886:
869:
868:
864:
812:
811:
807:
798:
796:
788:
787:
778:
769:
767:
760:
759:
742:
733:
731:
722:
721:
717:
708:
706:
698:
697:
690:
681:
679:
670:
669:
662:
653:
651:
635:
634:
630:
620:
618:
610:
609:
602:
593:
591:
583:
582:
573:
568:
506:
458:
420:ISSN 1476-4687.
286:
277:
237:
209:
181:Michel Sadelain
170:
158:
135:
88:
68:
53:Alma mater
48:
45:
36:
24:
17:
12:
11:
5:
1914:
1912:
1904:
1903:
1898:
1888:
1887:
1884:
1883:
1876:
1869:
1862:
1855:
1848:
1839:
1838:External links
1836:
1833:
1832:
1808:
1797:
1771:
1741:
1717:
1693:
1669:
1644:
1620:
1602:
1578:
1537:
1513:
1489:
1465:
1440:
1416:
1389:
1365:
1299:
1275:
1251:
1227:
1170:
1145:
1087:
1063:
1008:
984:
960:
895:
862:
825:(2): 215–223.
805:
776:
740:
715:
688:
660:
628:
600:
570:
569:
567:
564:
563:
562:
556:
550:
544:
538:
535:
532:
529:
526:
523:
516:
513:
505:
502:
501:
500:
497:
492:
486:
480:
474:
468:
462:
457:
454:
453:
452:
437:
422:
408:
405:ISSN 1946-6234
397:
387:
372:
362:
351:
334:
318:
309:
285:
282:
276:
273:
236:
233:
208:
205:
189:cell therapist
176:
175:
168:
164:
163:
160:
159:
157:
156:
150:
148:
144:
143:
137:
136:
134:
133:
127:
121:
115:
112:
109:
106:
103:
100:
96:
94:
90:
89:
87:
86:
83:
80:
76:
74:
73:Known for
70:
69:
67:
66:
63:
60:
56:
54:
50:
49:
46:
42:
38:
37:
34:
26:
25:
22:
15:
13:
10:
9:
6:
4:
3:
2:
1913:
1902:
1899:
1897:
1894:
1893:
1891:
1881:
1877:
1874:
1870:
1867:
1863:
1860:
1856:
1853:
1849:
1846:
1842:
1841:
1837:
1822:
1818:
1812:
1809:
1806:
1801:
1798:
1790:September 14,
1785:
1781:
1775:
1772:
1764:September 19,
1759:
1756:. Clarivate.
1755:
1751:
1745:
1742:
1731:
1730:BigMarker.com
1727:
1721:
1718:
1707:
1703:
1697:
1694:
1683:
1679:
1673:
1670:
1658:
1654:
1648:
1645:
1634:
1630:
1624:
1621:
1616:
1612:
1606:
1603:
1592:
1588:
1582:
1579:
1574:
1570:
1565:
1560:
1556:
1552:
1548:
1541:
1538:
1527:
1523:
1517:
1514:
1503:
1499:
1493:
1490:
1479:
1475:
1469:
1466:
1454:
1450:
1444:
1441:
1430:
1426:
1420:
1417:
1406:
1402:
1396:
1394:
1390:
1379:
1378:www.mskcc.org
1375:
1369:
1366:
1361:
1357:
1353:
1349:
1345:
1341:
1337:
1333:
1329:
1325:
1321:
1317:
1313:
1306:
1304:
1300:
1289:
1285:
1279:
1276:
1265:
1261:
1255:
1252:
1241:
1237:
1231:
1228:
1223:
1219:
1215:
1211:
1207:
1203:
1198:
1193:
1189:
1185:
1181:
1174:
1171:
1159:
1158:www.mskcc.org
1155:
1149:
1146:
1141:
1137:
1132:
1127:
1123:
1119:
1115:
1111:
1107:
1103:
1099:
1091:
1088:
1077:
1073:
1067:
1064:
1059:
1055:
1051:
1047:
1043:
1039:
1035:
1031:
1027:
1023:
1019:
1012:
1009:
998:
994:
988:
985:
974:
970:
964:
961:
956:
952:
947:
942:
938:
934:
930:
926:
922:
918:
914:
910:
906:
899:
896:
885:
881:
877:
873:
866:
863:
858:
854:
849:
844:
840:
836:
832:
828:
824:
820:
816:
809:
806:
795:
791:
785:
783:
781:
777:
766:
763:
757:
755:
753:
751:
749:
747:
745:
741:
729:
725:
719:
716:
705:
701:
695:
693:
689:
677:
673:
667:
665:
661:
650:
646:
642:
638:
632:
629:
617:
613:
607:
605:
601:
590:
586:
580:
578:
576:
572:
565:
561:
557:
555:
551:
549:
545:
543:
539:
536:
533:
530:
527:
524:
521:
517:
514:
512:
508:
507:
503:
498:
496:
493:
490:
487:
484:
481:
478:
475:
472:
469:
467:
463:
460:
459:
455:
450:
446:
442:
438:
435:
431:
427:
423:
421:
417:
413:
409:
407:PMID 24553386
406:
403:
398:
396:
392:
388:
386:
382:
378:
373:
371:
368:
363:
360:
357:
352:
349:
346:
345:10.1038/nm827
343:
340:
335:
332:
329:
326:
323:
319:
317:
314:
310:
308:
305:
301:
298:
295:
292:
288:
287:
283:
281:
274:
272:
269:
268:β-thalassemia
265:
260:
258:
253:
249:
247:
243:
234:
232:
230:
226:
222:
218:
214:
206:
204:
202:
198:
194:
190:
186:
182:
173:
169:
165:
161:
155:
152:
151:
149:
145:
142:
138:
132:
128:
126:
122:
120:
116:
113:
110:
107:
104:
101:
98:
97:
95:
91:
84:
81:
78:
77:
75:
71:
64:
61:
58:
57:
55:
51:
47:Paris, France
43:
39:
32:
27:
20:
1824:. Retrieved
1820:
1811:
1800:
1788:. Retrieved
1783:
1774:
1762:. Retrieved
1753:
1744:
1733:. Retrieved
1729:
1720:
1709:. Retrieved
1705:
1696:
1685:. Retrieved
1681:
1672:
1661:. Retrieved
1659:. 2018-10-16
1656:
1647:
1636:. Retrieved
1632:
1623:
1614:
1605:
1594:. Retrieved
1590:
1581:
1554:
1550:
1540:
1529:. Retrieved
1525:
1516:
1505:. Retrieved
1501:
1492:
1481:. Retrieved
1477:
1468:
1457:. Retrieved
1455:. 2016-09-07
1452:
1443:
1432:. Retrieved
1428:
1419:
1408:. Retrieved
1404:
1381:. Retrieved
1377:
1368:
1319:
1315:
1291:. Retrieved
1287:
1278:
1267:. Retrieved
1263:
1254:
1243:. Retrieved
1240:ascopost.com
1239:
1230:
1187:
1183:
1173:
1162:. Retrieved
1160:. 2014-02-19
1157:
1148:
1105:
1101:
1090:
1079:. Retrieved
1075:
1066:
1028:(1): 70–75.
1025:
1021:
1011:
1000:. Retrieved
996:
987:
976:. Retrieved
973:www.wbur.org
972:
963:
912:
908:
898:
887:. Retrieved
875:
865:
822:
818:
808:
797:. Retrieved
793:
768:. Retrieved
764:
732:. Retrieved
727:
718:
707:. Retrieved
703:
680:. Retrieved
675:
652:. Retrieved
640:
631:
619:. Retrieved
615:
592:. Retrieved
589:ascopost.com
588:
278:
261:
254:
250:
245:
238:
210:
180:
179:
147:Institutions
140:
1682:BrandeisNOW
1288:www.sec.gov
1190:(7): 1471.
678:(in French)
456:Memberships
1890:Categories
1826:2024-09-13
1735:2020-09-03
1711:2020-09-03
1687:2020-07-15
1663:2020-07-15
1638:2020-07-15
1596:2020-07-15
1531:2020-07-15
1507:2020-07-15
1483:2020-07-15
1459:2020-07-15
1434:2021-08-03
1410:2020-07-15
1383:2021-08-03
1293:2020-09-03
1269:2020-09-03
1245:2020-09-03
1164:2020-09-03
1081:2020-09-03
1002:2020-09-03
978:2020-09-03
889:2023-09-13
799:2020-07-15
770:2020-07-15
734:2024-04-14
709:2024-09-13
682:2024-09-13
654:2020-06-15
594:2021-08-03
566:References
302:0022-1007
1617:. NYSTEM.
1573:2159-8274
1344:1476-4687
1206:0092-8674
1122:1946-6234
1042:1087-0156
937:1476-4687
884:0362-4331
839:1879-0372
649:1059-1028
350:1546-170X
333:1546-1696
1758:Archived
1352:10894546
1222:43075053
1214:29245005
1140:23515080
1058:20302096
1050:11753365
955:28225754
857:19327974
621:June 15,
449:29326244
434:29385376
385:23515080
235:Research
1629:"Award"
1360:4355996
1324:Bibcode
1131:3742551
946:5558614
917:Bibcode
848:5548385
485:(ASGCT)
307:9705944
275:Patents
248:locus.
167:Website
1571:
1358:
1350:
1342:
1316:Nature
1220:
1212:
1204:
1138:
1128:
1120:
1056:
1048:
1040:
953:
943:
935:
909:Nature
882:
855:
845:
837:
647:
504:Awards
479:(ASCI)
473:(AACR)
447:
432:
383:
93:Awards
1356:S2CID
1218:S2CID
1054:S2CID
641:Wired
616:MSKCC
558:2024
552:2024
546:2024
540:2023
518:2018
509:2012
491:(ASH)
129:2024
123:2024
117:2024
1792:2023
1766:2023
1569:ISSN
1348:PMID
1340:ISSN
1210:PMID
1202:ISSN
1184:Cell
1136:PMID
1118:ISSN
1046:PMID
1038:ISSN
997:Time
951:PMID
933:ISSN
880:ISSN
853:PMID
835:ISSN
645:ISSN
623:2020
464:The
445:PMID
430:PMID
381:PMID
348:ISSN
331:ISSN
304:PMID
300:ISSN
246:TRAC
242:scFv
187:and
44:1960
41:Born
1559:doi
1332:doi
1320:406
1192:doi
1188:171
1126:PMC
1110:doi
1030:doi
941:PMC
925:doi
913:543
843:PMC
827:doi
342:doi
325:doi
294:doi
229:NIH
191:at
1892::
1819:.
1782:.
1752:.
1728:.
1704:.
1680:.
1655:.
1631:.
1613:.
1589:.
1567:.
1553:.
1549:.
1524:.
1500:.
1476:.
1451:.
1427:.
1403:.
1392:^
1376:.
1354:.
1346:.
1338:.
1330:.
1318:.
1314:.
1302:^
1286:.
1262:.
1238:.
1216:.
1208:.
1200:.
1186:.
1182:.
1156:.
1134:.
1124:.
1116:.
1104:.
1100:.
1074:.
1052:.
1044:.
1036:.
1026:20
1024:.
1020:.
995:.
971:.
949:.
939:.
931:.
923:.
911:.
907:.
878:.
874:.
851:.
841:.
833:.
823:21
821:.
817:.
792:.
779:^
743:^
726:.
702:.
691:^
674:.
663:^
643:.
639:.
614:.
603:^
587:.
574:^
418:.
223:,
203:.
1829:.
1794:.
1768:.
1738:.
1714:.
1690:.
1666:.
1641:.
1599:.
1575:.
1561::
1555:3
1534:.
1510:.
1486:.
1462:.
1437:.
1413:.
1386:.
1362:.
1334::
1326::
1296:.
1272:.
1248:.
1224:.
1194::
1167:.
1142:.
1112::
1106:5
1084:.
1060:.
1032::
1005:.
981:.
957:.
927::
919::
892:.
859:.
829::
802:.
773:.
737:.
712:.
685:.
657:.
625:.
597:.
451:.
436:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
